Moderna’s Low-Dose COVID-19 Vaccine Wins FDA Approval, First for Older Adults and High-Risk Groups

COVID-19 vaccines are no longer at the peak of a global emergency vaccination campaign, but the virus continues to reappear during respiratory disease seasons, and the questions around vaccine development have therefore changed: not whether a first-generation product can be made quickly, but whether a balance can be found among lower dose, clearer population positioning, and sustainable supply. Moderna’s next-generation COVID-19 vaccine mNEXSPIKE has been approved by the U.S. Food and Drug Administration, making it a notable case in this context.

Moderna said the FDA has approved mNEXSPIKE for adults aged 65 and older, as well as people aged 12 to 64 who have at least one underlying disease or condition that increases the risk of severe disease. Product pages and approval documents later released by the FDA also state that the product’s formal name is COVID-19 Vaccine, mRNA, its brand name is MNEXSPIKE, and its manufacturer is ModernaTX, Inc.; the approved indication is active immunization to prevent COVID-19 disease caused by SARS-CoV-2.

This vaccine is not simply a “dose-reduced” version of an existing formulation. The FDA review summary states that mNEXSPIKE corresponds to the development code mRNA-1283, whose mRNA encodes the N-terminal domain and receptor-binding domain of the coronavirus spike protein, rather than the full-length spike protein used in Moderna’s earlier COVID-19 vaccine. In other words, it seeks to support a lower-dose vaccination strategy through a more focused immune target.

On clinical data, the FDA summary mentions a Phase 3 study that randomized 11,454 participants to receive 10 micrograms of mRNA-1283.222 or 50 micrograms of Moderna’s bivalent COVID-19 vaccine. The primary efficacy analysis showed that, compared with the control vaccine, mNEXSPIKE achieved a relative vaccine efficacy of 9.31%, meeting the FDA’s predefined non-inferiority criterion. This is not the same as claiming it is superior in all scenarios, but it supports its use as a lower-dose option under the review setting.

The FDA approval letter was dated May 30, 2025, and limited the eligible population to people who had received any COVID-19 vaccine and who are either aged 65 and older or aged 12 to 64 and in a high-risk group. The letter also allows Moderna to market a single-dose 0.2 mL prefilled syringe under the MNEXSPIKE brand name, with packaging formats of 1, 2, or 10 syringes. These details show that what regulators approved is not a universal vaccine intended to broadly replace existing products, but a booster immunization tool with clear population boundaries.

Safety remains an unavoidable part of mRNA vaccine review. FDA documents state that no specific safety concerns were seen in the older population during the review, and efficacy results in older participants were also consistent with those in younger adults; however, the approval also comes with postmarketing safety requirements, including myocarditis and pericarditis reporting and a retrospective cohort study. This means the regulatory judgment does not treat risk as fully closed, but continues to accumulate real-world data after approval.

From the perspective of market and public health policy, mNEXSPIKE is more like a second option in Moderna’s COVID-19 vaccine portfolio than a replacement for Spikevax. The Associated Press reported that Moderna expected to offer two choices in fall 2025; at the same time, the more restricted approval scope also echoes the direction the FDA has taken with other COVID-19 vaccine options. As COVID-19 vaccines shift from emergency mass deployment to seasonal, high-risk-oriented use, competition in platform technologies will also move from “fastest to market” toward long-term comparisons of dose, tolerability, breadth of protection, and policy fit.